Fosifloxuridine nafalbenamide
- Generic Name
- Fosifloxuridine nafalbenamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H29FN3O9P
- CAS Number
- 1332837-31-6
- Unique Ingredient Identifier
- 4YO6QT3SZ9
- Background
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
- Associated Conditions
- -
- Associated Therapies
- -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 91
- Registration Number
- NCT05714553
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 182
- Registration Number
- NCT05678257
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.